Delineating COVID-19 immunological features using single-cell RNA sequencing
Understanding the molecular mechanisms of coronavirus disease 2019 (COVID-19) pathogenesis and immune response is vital for developing therapies. Single-cell RNA sequencing has been applied to delineate the cellular heterogeneity of the host response toward COVID-19 in multiple tissues and organs. H...
Gespeichert in:
Veröffentlicht in: | Innovation (New York, NY) NY), 2022-09, Vol.3 (5), p.100289-100289, Article 100289 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Understanding the molecular mechanisms of coronavirus disease 2019 (COVID-19) pathogenesis and immune response is vital for developing therapies. Single-cell RNA sequencing has been applied to delineate the cellular heterogeneity of the host response toward COVID-19 in multiple tissues and organs. Here, we review the applications and findings from over 80 original COVID-19 single-cell RNA sequencing studies as well as many secondary analysis studies. We describe that single-cell RNA sequencing reveals multiple features of COVID-19 patients with different severity, including cell populations with proportional alteration, COVID-19-induced genes and pathways, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in single cells, and adaptation of immune repertoire. We also collect published single-cell RNA sequencing datasets from original studies. Finally, we discuss the limitations in current studies and perspectives for future advance.
[Display omitted]
•Single-cell RNA sequencing is a powerful biotechnology in COVID-19 research•It reveals multiple features of SARS-CoV-2 pathogenesis and host immune response•Single-cell immune profiling characterizes the adaptive immune response in COVID-19•Analysis of B cell receptors accelerates the neutralizing antibody identification |
---|---|
ISSN: | 2666-6758 2666-6758 |
DOI: | 10.1016/j.xinn.2022.100289 |